LAPTM4B and prostate carcinoma: Studies have shown that the LAPTM4B polymorphism is associated with susceptibility to a variety of solid tumors, such as HCC (9), breast cancer (10–12), non-small cell lung cancer (13), gastric cancer (14), cervical cancer (15), endometrial carcinoma (16), diffuse large b-cell lymphoma (17, 18), gallbladder cancer (19), ovarian cancer (20), papillary thyroid cancer (21), pancreatic cancer (22), and prostate cancer (23).